KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Revenue (2016 - 2025)

Historic Revenue for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $693.2 million.

  • Bio-Rad Laboratories' Revenue rose 385.02% to $693.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.6 billion, marking a year-over-year increase of 65.07%. This contributed to the annual value of $2.6 billion for FY2025, which is 65.07% up from last year.
  • According to the latest figures from Q4 2025, Bio-Rad Laboratories' Revenue is $693.2 million, which was up 385.02% from $653.0 million recorded in Q3 2025.
  • Over the past 5 years, Bio-Rad Laboratories' Revenue peaked at $747.0 million during Q3 2021, and registered a low of $585.4 million during Q1 2025.
  • Its 5-year average for Revenue is $677.3 million, with a median of $680.9 million in 2022.
  • As far as peak fluctuations go, Bio-Rad Laboratories' Revenue skyrocketed by 3333.95% in 2021, and later plummeted by 975.18% in 2024.
  • Quarter analysis of 5 years shows Bio-Rad Laboratories' Revenue stood at $732.8 million in 2021, then fell by 0.34% to $730.3 million in 2022, then fell by 6.72% to $681.2 million in 2023, then dropped by 2.01% to $667.5 million in 2024, then rose by 3.85% to $693.2 million in 2025.
  • Its last three reported values are $693.2 million in Q4 2025, $653.0 million for Q3 2025, and $651.6 million during Q2 2025.